Nancy supports the Citeline editorial team with design and multimedia projects, including infographics, data visualizations, and UI/UX. She holds a BA in Journalism and previously worked at US News & World Report as a digital producer. In her spare time, Nancy enjoys traveling, being outdoors, and attending concerts.
Latest from Nancy Pham
INFOGRAPHIC: 2024 was a particularly quiet year for biopharma M&A, with no buyouts reaching the $5bn threshold, while alliance volume and valuations declined compared to 2023, as well.
CBER has at least 14 and CDER another 10 novel biologics among the more than 60 candidates with a user fee goal in 2025.
Review times for all 61 novel agents the US FDA approved in 2024.
In this instalment of HBW Insight’s “Inside Regulatory Affairs” series, AdverCheck managing directors Lucy Rochford and James Walmsley describe how the consumer health industry is increasingly outsourcing its advertising copy review as it moves closer to the fast-moving consumer goods sector. They also point to a worrying trend in the UK of advertising prescription-only medicines online.
In this installment of HBW Insight’s "Inside Regulatory Affairs” series, The Honey Pot Company’s Kristini Miles discusses the challenges of communicating science to today’s consumer, progress in policy benefiting historically disadvantaged communities, and the numerous other demands that occupy her day-to-day.
In this installment of HBW Insight’s “Inside Regulatory Affairs” series, Bayer Consumer Health’s global regulatory director, Jenny Holmes, describes how the job has changed in recent years to assume an enabling role for innovation.